非小细胞肺癌吉西他滨化疗敏感性预测  

Study of Gemcitabine chemosensitivity prediction in non-small cell lung cancer

作　　者：吴鹏[1] 徐佳佳[2] 王国庆[2] 冯俊志[1] 施风[1] 

机构地区：[1]江苏建康职业学院医学护理系,江苏南京211800 [2]东南大学附属中大医院病理科,江苏南京210009

出　　处：《中国医药导报》2014年第23期43-46,共4页China Medical Herald

基　　金：江苏建康职业学院院级教科研项目(编号JK201104)

摘　　要：目的探讨非小细胞肺癌(NSCLC)吉西他滨(GEM)化疗敏感性预测靶标。方法 30例NSCLC组织,体外药敏试验明确GEM IC50值;Realtime-PCR检测GEM代谢酶hENT1、dCK、RRM1和RRM2 mRNA表达水平。结果hENT1、dCK、RRM1和RRM2单个基因表达量与GEM IC50值无关(P>0.05);(hENT1×dCK)/(RRM1×RRM2)值与GEM IC50值呈负相关(P<0.001)。结论 (hENT1×dCK)/(RRM1×RRM2)值可作为GEM化疗敏感性预测的潜在标志物。Objective To explore biomarker of Gemcitabine （GEM） chemosensitivity in non-small cell lung cancer （NSCLC）. Methods GEM IC50 of 30 NSCLC tissues were detected by susceptibility testing in vitro, mRNA expression of hENT1, dCK ,RRM1 and RRM2 were determined by Realtime-PCR. Results hENT1, dCK, RRM1 or RRM2 expression levels in individual gene had no relationship with the GEM IC50 value （P ＆gt; 0.05）, however, ratio of （hENT1×dCK）/（RRM1×RRM2） was negatively correlated with GEM IC50 value （P 〈 0.001）. Conclusion Ratio of （hENT1×dCK）/（RRM1×RRM2） may predict GEM chemosensitivity in NSCLC.

关 键 词：非小细胞肺癌 吉西他滨 化疗敏感性 原代细胞 

分 类 号：R734.2[医药卫生—肿瘤] R730.54[医药卫生—临床医学]